Background: Since December 2019, SARS-CoV-2, otherwise known as coronavirus disease 2019 (COVID-19), has caused worldwide panic and is now a serious problem. As the situation worsens, the need for an official cure becomes more crucial and different methods are being considered for treating infected COVID-19 patients. Objectives: This study aimed to emphasize and further elaborate on the existing and possible treatment methods against COVID-19 and assess the awareness of healthcare professionals (doctors, medical technologists, and nurses) on the treatments for COVID-19. Methodology: The study utilized an exploratory sequential mixed methods design following the treatment and misinformation theories models. The respondents were selected based on inclusion and exclusion criteria and recruited through the snowball sampling technique. The study used an adapted survey questionnaire on the pathophysiology of COVID-19 and possible treatment options. Descriptive statistical analysis for quantitative data and open thematic coding is used in an online qualitative deductive data analysis. Results: Based on the data, webinars, lectures, and discussions were the primary source of information among healthcare professionals. Most of the respondents showed proficiency with remdesivir among investigational selective medicines. Chloroquine was the top choice among selected repurposed drugs. They were aware of the convalescent plasma therapy that uses antibodies from the blood plasma of recovered COVID-19 patients. They were not aware of the different herbal treatments used to treat COVID-19. Conclusion Hence, chloroquine (repurposed drug), remdesivir (investigational drug), and convalescent plasma (adjunctive therapy) are the most well-known treatments for COVID-19. Most of the respondents were aware of the action and side effects of chloroquine, remdesevir, and convalescent plasma therapy.
COVID-19 ; Drugs, Investigational ; Herbal

Authors introduced some classes of drugs for treating rheumatic arthritis. Basic drug group includes biological agents, anti TNF drugs such as Entanercept- Enbrel; Infliximab; Adalimumab- Humira. In non-steroidal anti-inflammatory drugs (NSAIDs) group, there are Meloxixam - Mobic; Nimesulide- B- Nalgesine; Nise, Celecoxib- Celebrex; Rofecoxib- Vioxx; Valdecoxib-Bextra; Parecoxib- Dynastat; Etoricoxib-arcoxia. Group of slow released antirheumatic drugs included diacetylrÐine or diacerhÐine (ART 50). A new therapy that gave rapid and long lasting pain relieve, more viscosity of articular fluid is administration of sodium hyaluronate (Hyalgan, Ostenil, Hyruan) intra-articular injection
Antirheumatic Agents ; Drugs, Investigational ; Pharmaceutical Preparations

A survey on PPA-containing products consumption was conducted in 10 pharmacies located in Hanoi from February to May 2002. It revealed that there were 20 such products available in the market(of them, 16 were domestic). The PPA content as base form in a single dose of all these preparations was not exceeded 25mg. During the studied period, out of 250 people buying medication for cough and cold, 74 people (29.6% bought PPA-containing products with the most purchased ones were Decolgen forte and Rhumenol. Many patients with cough and cold consumed relatively high amount of PPA, not being aware of its adverse effects and contraindications
Pharmacy ; Analgesics, Non-Narcotic ; utilization ; Drugs, Investigational

Data of circulating registered medications of nationwide manufacturing centers from 1996 to 2001 was reviewed. The data was processed by common statistic methods with tests to compare between result group, using Epi-info software version 6.04. By 2001, the total of circulating medications were 6,875. 5,187 medications out of which is that of state businesses and 1,689 medications is that of out-of-state businesses. For types, both types of business have tend to seek the medications that give high benefit, as presented in structure of registration. Brand name drugs, herbals with new names and new formulations have tend to increase, compare to common and essential medications
Pharmaceutical Preparations ; Drugs, Investigational ; Evaluation Studies

Drugs, Chinese Herbal ; chemistry ; Drugs, Investigational ; Humans ; Plasma

Drugs, Investigational ; Humans ; Lymphoma ; drug therapy ; United States

Child ; Clinical Trials as Topic ; ethics ; Drugs, Investigational ; Humans

OBJECTIVETo review the experimental drugs for the treatment of autoimmune myocarditis.

DATA SOURCESThe literatures published in English about different kinds of experimental drugs based on different therapeutic mechanisms for the treatment of autoimmune myocarditis were obtained from PubMed from 2002 to 2013.

STUDY SELECTIONOriginal articles regarding the experimental drugs for treatment of autoimmune myocarditis were selected.

RESULTSThis study summarized the effects of the experimental drugs for the treatment of autoimmune myocarditis, such as immunomodulators and immunosuppressants, antibiotics, Chinese medicinal herbs, cardiovascular diseases treatment drugs, etc. These drugs can significantly attenuate autoimmune myocarditis-induced inflammation and fibrosis, alleviate autoimmune myocarditis-triggered overt lymphocyte proliferation, and meanwhile reduce Th1 cytokines (IFN-γ and IL-2) and increase Th2 cytokines (IL-4 and IL-10).

CONCLUSIONThis study summarized recent advances in autoimmune myocarditis treatment and further proposes that traditional Chinese medicine and immune regulators will play important roles in the future.

Animals ; Autoimmune Diseases ; drug therapy ; Drugs, Investigational ; therapeutic use ; Humans ; Medicine, Chinese Traditional ; Myocarditis ; drug therapy ; Therapies, Investigational ; trends

Drug Combinations ; Drug Design ; Drugs, Chinese Herbal ; pharmacology ; Drugs, Investigational ; Humans

Atherosclerosis ; drug therapy ; China ; Drugs, Chinese Herbal ; therapeutic use ; Humans ; Medicine, Chinese Traditional ; Therapies, Investigational